Antisense modulation of apolipoprotein B expression
AssigneeGenzyme Corporation
InventorsRoseanne M. Crooke, Mark Graham, Susan M. Freier
Life of this patent
Estimating the term…
Abstract
Antisense compounds, compositions and methods are provided for modulating the expression of apolipoprotein B. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding apolipoprotein B. Methods of using these compounds for modulation of apolipoprotein B expression and for treatment of diseases associated with expression of apolipoprotein B are provided.
Claims57
An antisense oligonucleotide 20 to 30 nucleobases in length, or a pharmaceutically acceptable salt form thereof, wherein the antisense oligonucleotide has a nucleobase sequence comprising the nucleobase sequence of SEQ ID NO:247.
An antisense oligonucleotide 20 nucleotides in length having the sequence of nucleobases as set forth in SEQ ID NO:247 and comprising 5-methylcytosine at nucleobases 2, 3, 5, 9, 12, 15, 17, 19, and 20, wherein every internucleoside linkage is a phosphorothioate linkage, nucleotides 1-5 and 16-20 are 2′-O-methoxyethyl nucleotides, and nucleotides 6-15 are 2′-deoxynucleotides, or wherein said antisense oligonucleotide is a pharmaceuticallv acceptable salt form thereof.
An antisense compound 12 to 30 nucleobases in length and fully complementary to SEQ ID NO:3, wherein said compound specifically hybridizes to the range of nucleotides 3230-3287 as set forth in SEQ ID NO:3, or a pharmaceutically acceptable salt thereof.
Dependencies are inferred from the claim text.